BACKGROUND: Improved survival after childhood cancer raises concerns over the possible long-term reproductive health effects of cancer therapies. We investigated whether children of female childhood cancer survivors are at elevated risk of being born preterm or exhibiting restricted fetal growth and evaluated the associations of different cancer treatments on these outcomes. METHODS: Using data from the Childhood Cancer Survivor Study, a large multicenter cohort of childhood cancer survivors, we studied the singleton live births of female cohort members from 1968 to 2002. Included were 2201 children of 1264 survivors and 1175 children of a comparison group of 601 female siblings. Data from medical records were used to determine cumulative prepregnancy exposures to chemotherapy and radiotherapy. Logistic regression was used to estimate odds ratios (ORs) for the association between quantitative therapy exposures and preterm (<37 weeks) birth, low birth weight (<2.5 kg), and small-for-gestational-age (SGA) (lowest 10th percentile) births. All statistical tests were two-sided. RESULTS: Survivors' children were more likely to be born preterm than the siblings' children (21.1% versus 12.6%; OR = 1.9, 95% confidence interval [CI] = 1.4 to 2.4; P<.001). Compared with the children of survivors who did not receive any radiotherapy, the children of survivors treated with high-dose radiotherapy to the uterus (>500 cGy) had increased risks of being born preterm (50.0% versus 19.6%; OR = 3.5, 95% CI = 1.5 to 8.0; P = .003), low birth weight (36.2% versus 7.6%; OR = 6.8, 95% CI = 2.1 to 22.2; P = .001), and SGA (18.2% versus 7.8%; OR = 4.0, 95% CI = 1.6 to 9.8; P = .003). Increased risks were also apparent at lower uterine radiotherapy doses (starting at 50 cGy for preterm birth and at 250 cGy for low birth weight). CONCLUSIONS: Late effects of treatment for female childhood cancer patients may include restricted fetal growth and early births among their offspring, with risks concentrated among women who receive pelvic irradiation.
BACKGROUND: Improved survival after childhood cancer raises concerns over the possible long-term reproductive health effects of cancer therapies. We investigated whether children of female childhood cancer survivors are at elevated risk of being born preterm or exhibiting restricted fetal growth and evaluated the associations of different cancer treatments on these outcomes. METHODS: Using data from the Childhood Cancer Survivor Study, a large multicenter cohort of childhood cancer survivors, we studied the singleton live births of female cohort members from 1968 to 2002. Included were 2201 children of 1264 survivors and 1175 children of a comparison group of 601 female siblings. Data from medical records were used to determine cumulative prepregnancy exposures to chemotherapy and radiotherapy. Logistic regression was used to estimate odds ratios (ORs) for the association between quantitative therapy exposures and preterm (<37 weeks) birth, low birth weight (<2.5 kg), and small-for-gestational-age (SGA) (lowest 10th percentile) births. All statistical tests were two-sided. RESULTS: Survivors' children were more likely to be born preterm than the siblings' children (21.1% versus 12.6%; OR = 1.9, 95% confidence interval [CI] = 1.4 to 2.4; P<.001). Compared with the children of survivors who did not receive any radiotherapy, the children of survivors treated with high-dose radiotherapy to the uterus (>500 cGy) had increased risks of being born preterm (50.0% versus 19.6%; OR = 3.5, 95% CI = 1.5 to 8.0; P = .003), low birth weight (36.2% versus 7.6%; OR = 6.8, 95% CI = 2.1 to 22.2; P = .001), and SGA (18.2% versus 7.8%; OR = 4.0, 95% CI = 1.6 to 9.8; P = .003). Increased risks were also apparent at lower uterine radiotherapy doses (starting at 50 cGy for preterm birth and at 250 cGy for low birth weight). CONCLUSIONS: Late effects of treatment for female childhood cancerpatients may include restricted fetal growth and early births among their offspring, with risks concentrated among women who receive pelvic irradiation.
Authors: Daniel M Green; Eve M Peabody; Bin Nan; Susan Peterson; John A Kalapurakal; Norman E Breslow Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544
Authors: Daniel M Green; John A Whitton; Marilyn Stovall; Ann C Mertens; Sarah S Donaldson; Frederick B Ruymann; Thomas W Pendergrass; Leslie L Robison Journal: Am J Obstet Gynecol Date: 2002-10 Impact factor: 10.693
Authors: Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: Med Pediatr Oncol Date: 2002-04
Authors: Daniel M Green; John A Whitton; Marilyn Stovall; Ann C Mertens; Sarah S Donaldson; Frederick B Ruymann; Thomas W Pendergrass; Leslie L Robison Journal: J Clin Oncol Date: 2003-02-15 Impact factor: 50.717
Authors: Daniel M Green; Jane M Lange; Eve M Peabody; Natalia N Grigorieva; Susan M Peterson; John A Kalapurakal; Norman E Breslow Journal: J Clin Oncol Date: 2010-05-10 Impact factor: 44.544
Authors: Michael K Brawer; Stacy Loeb; Alan W Partin; Jayabalan Nirmal; Michael B Chancellor; J Curtis Nickel; Jacob Rajfer; Ellen Shapiro; Claus G Roehrborn Journal: Rev Urol Date: 2011
Authors: Christopher C Dvorak; Clarisa R Gracia; Jean E Sanders; Edward Y Cheng; K Scott Baker; Michael A Pulsipher; Anna Petryk Journal: Biol Blood Marrow Transplant Date: 2011-10-17 Impact factor: 5.742
Authors: Laura-Maria S Madanat; Nea Malila; Tadeusz Dyba; Timo Hakulinen; Risto Sankila; John D Boice; Päivi M Lähteenmäki Journal: Int J Cancer Date: 2008-12-15 Impact factor: 7.396
Authors: Raoul C Reulen; Maurice P Zeegers; W Hamish B Wallace; Clare Frobisher; Aliki J Taylor; Emma R Lancashire; Dave L Winter; Mike M Hawkins Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-08 Impact factor: 4.254
Authors: Jeanette F Winther; John D Boice; Jane Christensen; Kirsten Frederiksen; John J Mulvihill; Marilyn Stovall; Jørgen H Olsen Journal: Int J Cancer Date: 2010-12-15 Impact factor: 7.396
Authors: Laura-Maria Madanat-Harjuoja; Nea Malila; Päivi M Lähteenmäki; John D Boice; Mika Gissler; Tadeusz Dyba Journal: Int J Cancer Date: 2010-10-01 Impact factor: 7.396